The Role of Digital Twins in Drug Development
Digital twins transform pharma by simulating trials, predicting failures, and optimizing manufacturing for faster, safer drug development.
Digital twins are emerging as a transformative technology in pharmaceutical drug development and manufacturing. A digital twin is a virtual, data-driven counterpart of a physical object, process, or system that remains synchronized with its real-world equivalent.1 By integrating real-time data, advanced analytics, and artificial intelligence, digital twins allow pharmaceutical companies to simulate production environments, test scenarios, and predict failures before they occur. This capability is reshaping how drugs are developed by simulating clinical trial outcomes, drug formulation, and manufacturing efficiency.
In the pharmaceutical industry, digital twins may represent manufacturing equipment, production facilities, or even biological systems such as organs and patients. Unlike traditional modeling approaches, they continuously update as new data becomes available. This dynamic capability enables organizations to move beyond reactive responses to problems and instead make proactive, data-driven decisions based on simulated scenarios and predicted outcomes. In addition, the ongoing synchronization enables companies to monitor performance, simulate potential changes, and anticipate outcomes in real time. Examples include Sanofi simulating trial outcomes and CMC development as well as Novartis partnering with Zontal to develop digital lab models. An interesting read from colleagues at ZS Insight discussing digital twins within self-improving clinical trial operating models can be found here.
Digital twin systems rely on several key technological components.1 First, detailed three-dimensional models recreate the structure of the physical system being mirrored. Second, Internet of Things (IoT) sensors collect continuous data from equipment and processes such as temperature, pressure, or flow rates. Finally, artificial intelligence and advanced analytics process these data streams to identify patterns, simulate outcomes, and generate predictions. These components allow digital twins to mirror the behavior, performance, and structure of their real-world counterparts.
Pharmaceutical manufacturing involves highly controlled and complex environments where even small deviations can affect product quality. Digital twins allow companies to simulate entire production facilities and continuously track environmental conditions.1 For example, variations in humidity, airflow, or mixing conditions can be monitored and corrected in real time. By maintaining a synchronized digital model of the manufacturing environment, companies gain deeper insight into how small changes influence production outcomes.
Another advantage of digital twins is their ability to optimize pharmaceutical processes. Drug manufacturing involves intricate steps such as powder blending, crystallization, or sterile filtration. Digital twins can model these processes and test different operating conditions to determine which parameters produce the most consistent results. By simulating these conditions virtually, manufacturers can improve batch-to-batch consistency, enhance quality control, and minimize the risk of defective products reaching patients.2
Digital twins are also being applied earlier in the drug development process. Researchers are creating digital representations of biological systems and “virtual patients” that simulate how drugs interact with the human body.2 These models incorporate genetic, physiological, and biochemical data to predict how patients may respond to treatments. By testing drug candidates in virtual patient populations, researchers can identify promising therapies more efficiently and design more targeted clinical trials.
The use of digital twins in clinical trial modeling has the potential to significantly accelerate development timelines. Virtual patient models allow researchers to simulate how drugs may perform across different populations before conducting real-world studies. These simulations can help identify potential safety concerns, refine dosing strategies, and predict therapeutic outcomes.2 Some estimates suggest that digital twin technologies could reduce drug development timelines by up to 40 percent while improving the safety and efficiency of clinical trials.3
Scaling drug production from laboratory research to commercial manufacturing is one of the most challenging stages in pharmaceutical development. Small changes in equipment size, mixing conditions, or reaction kinetics can lead to unexpected outcomes during scale-up. Digital twins provide virtual prototypes of manufacturing processes, which allow engineers to test and refine production conditions before implementation in real facilities.4 This capability reduces risk, prevents costly errors, and improves the likelihood of successful large-scale manufacturing.4
Digital twins are rapidly transforming the pharmaceutical industry by enabling companies to simulate production environments, predict failures, and optimize complex drug development processes. Through the integration of real-time data, artificial intelligence, and advanced modeling, these virtual replicas provide powerful insights into both manufacturing systems and biological responses to medications. As adoption continues to grow, digital twins will likely play a central role in improving efficiency, reducing costs, and accelerating the delivery of safe and effective medicines to patients.
Resources:
- Saratkar SY, Langote M, Kumar P, Gote P, Weerarathna IN, Mishra GV. Digital Twin for Personalized Medicine Development. Front Digit Health. 2025;7:1583466.
- Maharjan R, Kim NA, Kim KH, Jeong SH. Transformative Roles of Digital Twins from Drug Discovery to Continuous Manufacturing: Pharmaceutical and Biopharmaceutical Perspectives. Int Journ Pharm. 2025;10:100409.
- Baddam H. LinkedIn. Digital Twins in Life Sciences: Simulating Success Before Trials Begin. 2025.
- Bordukova M, Makarov N, Rodriguez-Esteban R, Schmich F, Menden MP. Generative Artificial Intelligence Empowers Digital Twins in Drug Discovery and Clinical Trials. Expert Opin Drug Discov. 2024;19(1):33-42.
*Information presented on RxTeach does not represent the opinion of any specific company, organization, or team other than the authors themselves. No patient-provider relationship is created.